Jefferies analyst Kelly Shi downgraded ImmunoGen (IMGN) to Hold from Buy with a $31 price target after the company agreed to be acquired by AbbVie (ABBV) for $31.26 per share in cash.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMGN:
- AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and Dealmaker
- ImmunoGen downgraded to Hold from Buy at Canaccord
- ImmunoGen downgraded to Neutral from Buy at H.C. Wainwright
- ImmunoGen downgraded to Hold from Buy at Truist
- M & A News: AbbVie’s (NYSE:ABBV) $10.1B Gamble on ImmunoGen Sends Shares Soaring
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue